The high cost of cancer drugs and what we can do about it.
about
Epigallocatechin Gallate Nanodelivery Systems for Cancer TherapyAccountable care organizations and the practice of oncologyDefining and Measuring the Affordability of New Medicines: A Systematic Review.Improving access to high-cost cancer drugs in Latin America: Much to be done.Me, TooInternational comparison of the factors influencing reimbursement of targeted anti-cancer drugs.Hurdles and delays in access to anti-cancer drugs in Europe.Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.Patterns of cancer care costs in a country with detailed individual data.Phytomedicine in the Treatment of Cancer: A Health Technology AssessmentAdvanced therapy medicinal products: current and future perspectivesPerceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.Variation of Cost among Anti-cancer Drugs Available in Indian Market.Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of fundingRepurposing itraconazole as an anticancer agent.Opportunities to significantly reduce expenditure associated with cancer drugs.Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib.Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control Costs.From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.Integrating value assessment into discussions about the price of cancer drugs.Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward.Cancer Prevention and Treatment by Wholistic Nutrition.The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?Metastatic anorectal melanomas - An exploratory retrospective analysis on the benefits of systemic therapy versus best supportive care in a resource-limited setting from India.Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model.Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients.Rising cost of anticancer drugs in Australia.New tools for old drugs: Functional genetic screens to optimize current chemotherapy.Public Health Care Financing and the Costs of Cancer Care: A Cross-National Analysis.Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan.Detection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53Health services costs for cancer care in Australia: Estimates from the 45 and Up Study
P2860
Q26746909-AD12C8C8-C6CF-4AFB-B5C9-6EA27D0D77BCQ27026198-70FA8281-14FC-4E57-8D7B-AA06D9E3C9BFQ30234551-D0CE3F9D-8936-4AF3-AC71-5214C44A396FQ30235988-743CAC28-3E10-4A59-8251-96CF93FEFA8AQ33866095-16A45F58-2D36-42B2-98C8-84EAFBE63AFBQ34643295-B8D347A5-0D24-479B-905D-A2A6FEC5E192Q34680656-C0A91524-BB4A-4D94-A977-95F5CF766BB0Q35126801-78E6AF6A-F3D9-4FFC-BBBF-A26F07D36743Q35231615-2F515C16-5644-435C-8010-D0A643E9FE58Q36476627-FCCC05B9-D1EA-4997-A91C-1E56335B175AQ36840842-9814D04F-9EBA-4CBC-AE22-75DBFC972773Q37373222-2D93B97C-2F30-441B-A30C-862F5997AAA8Q37543021-0D0FAB2C-CF0F-4694-99D9-FD81EE0C0912Q37612154-8979C1EB-DEC1-4B54-AB4A-C60360556830Q38633691-171E0AA9-1C94-49A0-9630-0C44C884EB27Q38673820-90B94457-DBD3-4CEA-A5A7-5E167FB2B473Q38721743-B18BA1EB-5AEA-4839-B092-1E67B5CB4EA1Q38814615-2D01A108-E91B-4033-90CA-795CDB52008EQ38981247-5BD15218-F37E-45CD-BD60-85482B92A457Q39012934-FBEB83A8-5DAD-439E-BCD5-FF3B70122B94Q39060269-D93BACAF-4C53-40FD-AC97-A01C76D09CB4Q42337498-3DD30AF5-3993-4D57-994E-29C8AC9C7D89Q42355446-1A14A488-B8AE-4B60-915F-FB92EE2B0461Q43258142-CB1CDBDD-9FEF-4EBA-B14D-C9377164C689Q47664030-FFA3D437-2B02-4BCA-8F34-752BFBF053BAQ48068904-3D1BA446-B9CC-462E-AC03-53B6B872858DQ49423105-7CE345D1-9BF3-47E1-8E07-B3D2FE587B5AQ49430799-666328C8-79CA-4FF7-AFBB-E58C989DFD9BQ50001514-DD603399-DC69-4967-A41C-0D16AB1E9062Q51241237-EA60AB33-99DC-4F9D-85E1-4EB480A7D00CQ52430564-F4C899F7-2E95-431F-BF4A-C7D98F4BDAC3Q52591914-0722976C-4A10-4B8E-9568-4BF0B34737F9Q55224120-545F7F50-420B-4D49-8A10-979421345752Q55279429-7A20B98B-6CC3-423C-B933-F78D8EA93455Q57211763-BAA56C84-2F47-4E14-AC4C-955EF9F23A02Q58008153-E8E2CE4C-B4AD-4C3B-BC51-C099FECC2493
P2860
The high cost of cancer drugs and what we can do about it.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The high cost of cancer drugs and what we can do about it.
@ast
The high cost of cancer drugs and what we can do about it.
@en
type
label
The high cost of cancer drugs and what we can do about it.
@ast
The high cost of cancer drugs and what we can do about it.
@en
prefLabel
The high cost of cancer drugs and what we can do about it.
@ast
The high cost of cancer drugs and what we can do about it.
@en
P2860
P1476
The high cost of cancer drugs and what we can do about it.
@en
P2093
Mustaqeem Siddiqui
S Vincent Rajkumar
P2860
P304
P356
10.1016/J.MAYOCP.2012.07.007
P407
P577
2012-10-01T00:00:00Z